tailieunhanh - Báo cáo khoa học: "Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas | Bao et al. World Journal of Surgical Oncology 2010 8 52 http content 8 1 52 RESEARCH WORLD JOURNAL OF SURGICAL ONCOLOGY Open Access Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas Guoqiang Bao Qing Qiao Huadong Zhao and Xianli He Abstract Introduction HMGB1 High mobility group box 1 originally described as a nuclear protein is now regarded as a multifunctional protein with a paradoxical dual effect in tumors. In the present study HMGB1 overexpression and its correlation with the clinicopathologic characteristics and recurrence-free survival were evaluated in gastric adenocarcinomas. Methods 76 gastric adenocarcinomas surgically removed entered the study. The immunohistochemical staining was used to assess HMGB1 expression through tissue microarray procedure. The clinicopathologic characteristics of all patients were recorded and the regular follow-up was made for all patients. Results Almost all the gastric adenocarcinomas showed HMGB1 positive staining mainly in the nucleus and the overexpression of HMGB1 was found in cancerous tissues with higher strong reactivity rate compared with non-cancerous tissues total expression score 9 vs. P . Survival analysis revealed that tumor stage negatively correlated with cancer-free survival P . Furthermore HMGB1 overexpression positively associated with cancer-free survival of resectable gastric adenocarcinomas P . Conclusions The overexpression of HMGB1 protein indicates that HMGB1 may play a role in the tumorigenesis of gastric adenocarcinomas. And the overexpression of HMGB1 may be a marker of good prognosis of gastric adenocarcinoma given curative resection combined with adjuvant chemotherapy. Introduction Gastric cancer GC is the second most common cause of cancer-related death in the world. Many Asian countries including China have very high rates of GC. For patients in advanced stages the five-year survival rate is only about 20 percent. There are .